Overview

Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A (onabotulinumtoxinA) in treating patients with idiopathic overactive bladder with urinary incontinence.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Allergan
Treatments:
abobotulinumtoxinA
Botulinum Toxins
Botulinum Toxins, Type A
incobotulinumtoxinA
onabotulinumtoxinA
Criteria
Inclusion Criteria:

- Symptoms of OAB (frequency/urgency) with urinary incontinence for at least 6 months

- Inadequate response or limiting side effects with anticholinergics for the treatment
of OAB

Exclusion Criteria:

- Overactive Bladder caused by neurological condition

- Patient has predominance of stress incontinence

- History or evidence of pelvic or urological abnormality